TRIMETHYL-TETRADECYL-AMMONIUM CHLORIDE


Synonyms	Trimethyl-tetradecyl-ammonium chloride
Molecule Category	Salt-form
UNII	RMV7NJU3FX
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	CEYYIKYYFSTQRU-UHFFFAOYSA-M
Smiles	[Cl-].CCCCCCCCCCCCCC[N+](C)(C)C
InChI	InChI=1S/C17H38N.ClH/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18(2,3)4;/h5-17H2,1-4H3;1H/q+1;/p-1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C17H38N.Cl
Molecular Weight	291.94
AlogP	4.86
Hydrogen Bond Acceptor	0.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	13.0
Polar Surface Area	0.0
Molecular species	None
Aromatic Rings	0.0
Heavy Atoms	18.0

Assay Description	Organism	Bioactivity
Bactericidal activity against methicillin-susceptible Staphylococcus aureus IFO 12732 assessed as log10 reduction in viable cell count at 28 uM up to 120 min by agar dilution test	Staphylococcus aureus	99.9 %
Bactericidal activity against Escherichia coli IFO 3806 assessed as log10 reduction in viable cell count at 28 to 280 uM after 30 to 120 min by agar dilution test	Escherichia coli	None
Bactericidal activity against methicillin-susceptible Staphylococcus aureus IFO 12732 assessed as log10 reduction in viable cell count at 280 uM up to 30 min by agar dilution test	Staphylococcus aureus	None

Cross References

Resources	Reference
ChEMBL	CHEMBL109747
FDA SRS	RMV7NJU3FX
PubChem	20708
SureChEMBL	SCHEMBL69258

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).